Skip to main content
Contact Us
Subscribe
E-Edition
76°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bluebird Bio
(NQ:
BLUE
)
0.7091
+0.0038 (+0.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bluebird Bio
< Previous
1
2
3
4
5
6
7
8
9
Next >
bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
November 07, 2022
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference
November 02, 2022
From
bluebird bio, Inc.
Via
Business Wire
Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy
October 04, 2022
The risk-sharing agreement removes economic uncertainties, enabling regional and mid-sized health plans to provide patients with transfusion-dependent beta-thalassemia access to ZYNTEGLO
From
Real Endpoints
Via
GlobeNewswire
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)
September 16, 2022
From
bluebird bio, Inc.
Via
Business Wire
Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall
September 12, 2022
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces September Investor Events
August 29, 2022
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
August 17, 2022
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
August 17, 2022
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
August 04, 2022
From
bluebird bio, Inc.
Via
Business Wire
FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions
June 10, 2022
From
bluebird bio, Inc.
Via
Business Wire
FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy
June 09, 2022
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio stock trading halted today June 9th and tomorrow June 10th
June 09, 2022
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting
June 07, 2022
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress
May 09, 2022
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US
April 05, 2022
From
bluebird bio, Inc.
Via
Business Wire
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)
January 18, 2022
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference
January 11, 2022
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program
December 20, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor
December 17, 2021
From
bluebird bio, Inc.
Via
Business Wire
New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM
December 12, 2021
From
bluebird bio, Inc.
Via
Business Wire
New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels
December 11, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
November 22, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress
November 05, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row
November 05, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
November 04, 2021
From
bluebird bio, Inc
Via
Business Wire
bluebird bio Completes Planned Business Separation
November 04, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Sets Record Date and Distribution Date for Planned Business Separation
October 18, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Provides Update on Upcoming Planned Business Separation
October 08, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
September 21, 2021
From
bluebird bio, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.